{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:05:46Z","timestamp":1792868746294,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T00:00:00Z","timestamp":1527206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are approved for a wide range of malignancies. They work by priming the immune system response to cancer and have changed the landscape of available cancer treatments. As anticipated, modulation of the regulatory controls in the immune system with ICIs results in diverse immune-related adverse events, targeting any organ or gland. These toxicities are rarely fatal and generally regress after treatment discontinuation and\/or prescription of corticosteroids. Recently, several cases of ICI-related cardiotoxicity have been reported with complications ranging from cardiogenic shock to sudden death. The true incidence of ICI-associated myocarditis is likely underestimated, due to a combination of factors including the lack of specificity in the clinical presentation, the potential of overlap with other cardiovascular and general medical illnesses, the challenges in the diagnosis, and a general lack of awareness of this condition. Currently, there are no clear guidelines for surveillance, diagnosis, or management of this entity. There are multiple unresolved issues including, but not limited to, identifying those at risk of this uncommon toxicity, elucidating the pathophysiology, determining if and what type of surveillance is appropriate, optimal work-up of suspected patients, and methods for resolution of myocarditis. Here we describe a clinical vignette and discuss the salient features and management strategies of ICI-associated myocarditis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>The incidence of immune checkpoint inhibitor (ICI)-associated myocarditis is unclear and has been reported to range from 0.06% to 1% of patients prescribed an ICI. Myocarditis may be difficult to diagnose. The risk factors for ICI-associated myocarditis are not well understood but may include underlying autoimmune disease and diabetes mellitus. The prevalence of myocarditis has been reported to be higher with combination immune therapies. Myocarditis with ICI's typically occurs early, with an elevated troponin, may present with an normal left ventricular ejection fraction and may have a fulminant course. The optimal management of myocarditis associated with ICI's is unclear but most cases are treated with high-dose steroids.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0130","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T10:45:11Z","timestamp":1527245111000},"page":"879-886","source":"Crossref","is-referenced-by-count":270,"title":["Immune Checkpoint Inhibitor-Associated Myocarditis"],"prefix":"10.1093","volume":"23","author":[{"given":"Sarju","family":"Ganatra","sequence":"first","affiliation":[{"name":"Cardio-Oncology Program, Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston"},{"name":"Cardiac MR PET CT Program, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,25]]},"reference":[{"key":"2021122511050203800_onco12588-bib-0001","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122511050203800_onco12588-bib-0002","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122511050203800_onco12588-bib-0003","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122511050203800_onco12588-bib-0004","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"2021122511050203800_onco12588-bib-0005","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122511050203800_onco12588-bib-0006","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am College Cardiol"},{"key":"2021122511050203800_onco12588-bib-0007","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"2021122511050203800_onco12588-bib-0008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","article-title":"Cardiovascular toxicities associated with cancer immunotherapies","volume":"19","author":"Wang","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"2021122511050203800_onco12588-bib-0009","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ejhf.806","article-title":"Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia","volume":"19","author":"Berg","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2021122511050203800_onco12588-bib-0010","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer"},{"key":"2021122511050203800_onco12588-bib-0011","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"2021122511050203800_onco12588-bib-0012","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/annonc\/mdw141","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"27","author":"Naidoo","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122511050203800_onco12588-bib-0013","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2021122511050203800_onco12588-bib-0014","doi-asserted-by":"crossref","first-page":"e1361097","DOI":"10.1080\/2162402X.2017.1361097","article-title":"Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab","volume":"6","author":"Reuben","year":"2017","journal-title":"Oncoimmunology"},{"key":"2021122511050203800_onco12588-bib-0015","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","article-title":"CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes","volume":"101","author":"Love","year":"2007","journal-title":"Circ Res"},{"key":"2021122511050203800_onco12588-bib-0016","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"2021122511050203800_onco12588-bib-0017","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat Med"},{"key":"2021122511050203800_onco12588-bib-0018","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"key":"2021122511050203800_onco12588-bib-0019","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2169\/internalmedicine.33.659","article-title":"Serial electrocardiographic findings in acute myocarditis","volume":"33","author":"Nakashima","year":"1994","journal-title":"Intern Med"},{"key":"2021122511050203800_onco12588-bib-0020","first-page":"256","article-title":"Focal myocarditis mimicking acute ST-elevation myocardial infarction: Diagnosis using cardiac magnetic resonance imaging","volume":"33","author":"Testani","year":"2006","journal-title":"Tex Heart Inst J"},{"key":"2021122511050203800_onco12588-bib-0021","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijcard.2011.07.090","article-title":"ECG findings in comparison to cardiovascular MR imaging in viral myocarditis","volume":"165","author":"Deluigi","year":"2013","journal-title":"Int J Cardiol"},{"key":"2021122511050203800_onco12588-bib-0022","first-page":"SC12","article-title":"Predictors of mortality in paediatric myocarditis","volume":"10","author":"Abrar","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"2021122511050203800_onco12588-bib-0023","doi-asserted-by":"crossref","first-page":"H2596","DOI":"10.1152\/ajpheart.00215.2008","article-title":"Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis","volume":"294","author":"Ogawa","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2021122511050203800_onco12588-bib-0024","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","article-title":"Cardiovascular magnetic resonance in myocarditis: A JACC White Paper","volume":"53","author":"Friedrich","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2021122511050203800_onco12588-bib-0025","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.115.003584","article-title":"Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging","volume":"9","author":"Farhad","year":"2016","journal-title":"Circ Cardiovasc Imaging."},{"key":"2021122511050203800_onco12588-bib-0026","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/01.CIR.0000118493.13323.81","article-title":"Cardiovascular magnetic resonance assessment of human myocarditis: A comparison to histology and molecular pathology","volume":"109","author":"Mahrholdt","year":"2004","journal-title":"Circulation"},{"key":"2021122511050203800_onco12588-bib-0027","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2004.11.069","article-title":"Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: Comparison of different approaches","volume":"45","author":"Abdel-Aty","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2021122511050203800_onco12588-bib-0028","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.jacc.2017.08.050","article-title":"Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis","volume":"70","author":"Grani","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2021122511050203800_onco12588-bib-0029","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jacc.2017.08.044","article-title":"Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY Study","volume":"70","author":"Aquaro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2021122511050203800_onco12588-bib-0030","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0025-6196(12)61286-5","article-title":"Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: Implications for role of sampling error","volume":"64","author":"Hauck","year":"1989","journal-title":"Mayo Clin Proc"},{"key":"2021122511050203800_onco12588-bib-0031","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s000590050007","article-title":"Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report","volume":"25","author":"Maisch","year":"2000","journal-title":"Herz"},{"key":"2021122511050203800_onco12588-bib-0032","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122511050203800_onco12588-bib-0033","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","article-title":"Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy","volume":"2","author":"Suozzi","year":"2016","journal-title":"JAAD Case Rep"},{"key":"2021122511050203800_onco12588-bib-0034","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"2021122511050203800_onco12588-bib-0035","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1111\/j.1600-6143.2005.01074.x","article-title":"Antibody-mediated rejection in human cardiac allografts: Evaluation of immunoglobulins and complement activation products C4d and C3d as markers","volume":"5","author":"Rodriguez","year":"2005","journal-title":"Am J Transplant"},{"key":"2021122511050203800_onco12588-bib-0036","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.healun.2010.11.003","article-title":"Report from a consensus conference on antibody-mediated rejection in heart transplantation","volume":"30","author":"Kobashigawa","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"2021122511050203800_onco12588-bib-0037","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1600-6143.2006.01290.x","article-title":"Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report","volume":"6","author":"Kobashigawa","year":"2006","journal-title":"Am J Transplant"},{"issue":"suppl 15","key":"2021122511050203800_onco12588-bib-0038","first-page":"2012a","article-title":"Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy","volume":"35","author":"Santini","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122511050203800_onco12588-bib-0039","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122511050203800_onco12588-bib-0040","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122511050203800_onco12588-bib-0041","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122511050203800_onco12588-bib-0042","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122511050203800_onco12588-bib-0043","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdx755","article-title":"Comprehensive analysis of the clinical immuno-oncology landscape","volume":"29","author":"Tang","year":"2018","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0130","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0130","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/8\/879\/41915774\/oncolo_23_8_879.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/8\/879\/41915774\/oncolo_23_8_879.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:08:10Z","timestamp":1640412490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/8\/879\/6439657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,25]]},"references-count":43,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,5,25]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0130","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,8,1]]},"published":{"date-parts":[[2018,5,25]]}}}